Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.

We’re partnering with the University of Oxford – Oxford Cancer, the Oxford Vaccine Group, and the Pandemic Sciences Institute – to advance RNA vaccine development and accessibility for infectious diseases and cancer.

RNA vaccines have incredible potential to reshape healthcare, using genetic instructions to create immune responses that can prevent or treat disease.

With Oxford’s expertise in vaccine research and Univercells’ innovative RNA technology, we’re working to accelerate access to transformative and effective treatments.

Our goal?

More affordable, personalized cancer therapies and essential vaccines for diseases like dengue, Zika, and yellow fever.

This partnership is about turning innovation into real-world impact. Together, we’re pushing the boundaries of what’s possible in health.

Read more on the Oxford Cancer Website